Results 1 to 10 of about 1,279,543 (154)

Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases

Molecular Metabolism, 2021
Background: Therapies for metabolic diseases are numerous, yet improving insulin sensitivity beyond that induced by weight loss remains challenging. Therefore, search continues for novel treatment candidates that can stimulate insulin sensitivity and ...
Nina Sonne, Morten A. Karsdal, Kim Henriksen   +2 more
doaj   +3 more sources

Type 1 diabetes in the era of obesity: Pathophysiology and therapeutic implications. [PDF]

J Diabetes Investig
ABSTRACT Type 1 diabetes is defined by immune‐mediated beta‐cell failure and dependence on exogenous insulin. That definition is correct, but it may not fully describe many people seen in current clinical practice. Overweight and obesity are now common in type 1 diabetes, leading to variable combinations of high insulin requirement, hypertension ...
Bloomgarden Z.
europepmc   +2 more sources

Effect of GLP-1 receptor agonist on nutrient intake: A narrative review. [PDF]

Nutr Clin Pract
Abstract Humans have a primitive defense mechanism called metabolic adaptation that slows voluntary weight loss. It works by downregulating hormones that reduce food intake and by lowering the metabolic rate. Second‐generation GLP‐1 receptor agonists, such as semaglutide or tirzepatide, promote weight loss by targeting this hormonal system to control ...
Fujioka K.
europepmc   +2 more sources

Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics. [PDF]

Chemistry
A modular polyethylene glycol (PEG) scaffold enables rapid assembly of dual peptide agonists using strain‐promoted azide–alkyne cycloaddition (SPAAC) and copper‐catalysed azide–alkyne cycloaddition (CuAAC). Glucagon‐like peptide‐1 (GLP‐1) and amylin agonists were combined with controlled valency, yielding low‐picomolar activity and receptor‐selective ...
Kostadinova KA, Venne JL, Krajcovicova S, Dodgson J, Hogendorf WFJ, Nielsen TE, Hymel D, Bolt H, Collinson A, Day J, Revell J, Spring DR.   +11 more
europepmc   +2 more sources

Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies [PDF]

Metabolism Open
Obesity affects over 2 billion adults globally, with projections indicating that nearly two-thirds of adults will be affected by 2050. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed obesity treatment, achieving weight loss ...
Ioannis G. Lempesis, Maria Dalamaga
doaj   +2 more sources

Combination Pharmacotherapies for Obesity-Current Evidence and Future Directions. [PDF]

Endocrinol Diabetes Metab
Combination pharmacotherapy for obesity can enhance weight loss by targeting complementary neuroendocrine and metabolic pathways. Such benefits are largely additive but limited by tolerability, cost and access. This review outlines practical clinical archetypes and a research agenda for safer, more precise and durable combination strategies across ...
Kamrul-Hasan ABM, Kalra A, Kapoor N, Dutta D, Mahajan K, Maskey R, Raza SA.   +6 more
europepmc   +2 more sources

Amylin Revisited: A 5-Year Perspective on Its Emerging Role in the Treatment of Diabesity [PDF]

Journal of Obesity & Metabolic Syndrome
Amylin is a pancreatic peptide hormone that regulates blood glucose levels and appetite. This review outlines the physiological role of amylin and highlights recent clinical studies exploring its therapeutic potential in diabetes and obesity.
Chae Won Chung, Jaetaek Kim
doaj   +2 more sources

Novel Amylin‐Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta‐Analysis [PDF]

Endocrinology, Diabetes & Metabolism
Background Long‐acting amylin‐based therapies (ABTs) are emerging anti‐obesity agents; we sought to compare their effects on weight and anthropometric outcomes in adults with overweight/obesity without diabetes, evaluate gastrointestinal (GI) safety, and
A. B. M. Kamrul‐Hasan, Ibrahim Khalil, Kunal Mahajan, Deep Dutta, Mainak Banerjee, Joseph M. Pappachan   +5 more
doaj   +2 more sources

Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders [PDF]

Clinical and Molecular Hepatology
Obesity and its related metabolic comorbidities, including type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease, are increasingly recognized as heterogeneous and multisystemic disorders.
Yun Kyung Cho, Chang Hee Jung
doaj   +2 more sources

Emerging pharmacological targets in migraine therapy: CGRP and beyond [PDF]

Frontiers in Pharmacology
Migraine is a prevalent, complex, and disabling neurological disorder. Available treatments consist of repurposed drugs, with medication switching and treatment failure a common occurrence.
D. Atraszkiewicz, D. Dahiya
doaj   +2 more sources